The ESGO 2026 Congress, the 27th European Congress on Gynaecological Oncology, was held from February 26 to 28, 2026, in Copenhagen, Denmark. The congress brought together leading experts, clinicians, and researchers to discuss the latest advances in research, treatment, and patient care in gynaecological oncology.
The meeting featured more than 40 scientific sessions covering innovations in surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapies. It also included multidisciplinary discussions and live surgery sessions highlighting current developments in clinical practice.
15 Posts Not To Miss from ESGO 2026
Here are 15 interesting and informational posts that you shouldn’t miss from different professionals that visited and participated in the ESGO 2026.
European Society of Gynaecological Oncology:
“At the ESGO2026 Congress in Copenhagen, Professor Jalid Sehouli officially assumed the ESGO presidency! Professor Sehouli is the Medical Director of the Department of Gynaecology, including the centre of oncological surgery, at Charité – Universitätsmedizin Berlin.
He will serve on the Council with Past President Anna Fagotti, Vice President Viola Heinzelmann-Schwarz, President-Elect Ane Gerda Zahl Eriksson, Frederic Amant, Remi Nout, Alejandra Martinez, Nikolaos Thomakis, Zoltan Novak, Álvaro Tejerizo García, Basel Refky, Vladyslav Sukhin, Benedetta Guani, Karin Stålberg, Giovanni Aletti, Ranjit Manchanda and Michael Seckl as well as ENYGO President Houssein El Hajj and ESGO ENGAGe Co-Chairs Murat Gultekin and Anne De Middelaer.
Read more about his aims for his presidency.”
“Back from the European Society of Gynaecological Oncology Congress in Copenhagen, and still reflecting.
Yes, the scientific level was outstanding, the discussions sharp, the data impactful. But what stayed with me most was something less tangible. This congress reminded me how powerful it is to be part of a living scientific community, one that invests not only in research, but in people, mentorship, and education.
I am proud to be part of Fondazione Policlinico Universitario A. Gemelli IRCCS, an institution that continuously invests in the Society and in international collaboration, from its leadership to individual members. I truly felt this spirit during the celebration of Prof. Fagotti’s presidency, with Prof. Fanfani, Prof. Bizzarri and Prof. Marchetti.
As part of the latest Editorial Fellowship class at the International Journal of Gynecological Cancer (IJGC), I have had the privilege of crossing professional paths with Prof. Pedro Ramirez. Seeing him receive an award named after the late Prof. Scambia, a mentor who shaped so many of us, was powerful and deeply symbolic. It reminded me how lucky I am for the people I have met, so far, along my journey in gynecologic oncology.
Grateful for the science.
Even more grateful for the people.”
“Great presentations by the USB teams PD Dr Francis Jacob UniBS and Selina Fricke in the ESGO Translink and Database Sessions today at ESGO 2026 in Copenhagen!”
“Whether you’re a surgeon, a medical oncologist, or a patient advocate, the latest updates from the ESGO 2026 new Ovarian cancer guideline are: excellence in ovarian cancer care is built on specialization and holistic support.
Two recommendations from the newly released general recommendations stood out as essential for every clinical team to adopt from a cancer survivor perspective:
- Timely Referral to Specialized Centers: Patients with suspected primary or recurrent tubo-ovarian carcinoma should be referred to a gynecologic oncology center in a timely manner. It is also recommended that patients be informed if the center holds national or international accreditation, such as ESGO accreditation [III, A].
- Active Promotion of Support Groups: Beyond the operating room and the infusion suite, patient support groups should be promoted to provide assistance and guidance for patients, their families, and relatives throughout the entire treatment journey and beyond [IV, A].”
“From learning to dreaming bigger, ESGO Congress 2026 was a milestone in my journey as a future gyn oncologist.”
“ESGO2026 in Copenhagen, thrilled to have the privilege of co-authoring/leading 6 abstracts during the 27th European Society of Gynaecological Oncology Congress. Truly inspiring days of networking, learning, discussing… the future of Gynecologic Oncology with colleagues and friends and mentors.
Our research covered a wide spectrum of critical issues in our field.
Title: Evaluating the impact of standard operating procedures on gender balance among chairs at european society of gynaecological oncology (ESGO) meetings
Authors: Esra Bilir, Tibor Zwimpfer, Zoia Razumova, Joanna Kacperczyk-Bartnik, Ilker Kahramanoglu, Nicolò Bizzarri, Sara Nasser, Khayal Gasimli, Richárd Tóth, Tanja Nikolova, Aleksandra Strojna, Philippe Morice, Anna Fagotti, Nicole Concin
Read the Full Article.
Title: Managing patients with gynecologic cancer after urogynecologic alloplastic material implantation: current practices and attitudes
Authors: Esra Bilir, Andrzej Kuszka, Khayal Gasimli, Bettina Blau-Schneider, Sven Becker, Dominik Denschlag, Boris Gabriel, Sara Nasser
Read the Full Article.
Title: Assessment of chatGPT utilization and perceptions among gynecologic oncologists: A cross-sectional survey (TRSGO-AI-001)
Authors: Ibrahim Yalçin, Salih Taskin, Gözde Sahin, Mehmet Köse, Ugur Ortaç, Esra Bilir
Read the Full Article.
Title: Global trends and determinants of HRD and BRCA testing in ovarian cancer management: a cross-sectional study from the european network of young gynaecologic oncologists (ENYGO)
Authors: Tibor Zwimpfer, Houssein El Hajj, Esra Bilir, Matteo Lambertini, Rodrigo Sanchez-Bayona, Maria Kfoury, Joanna Kacperczyk-Bartnik, Martina Angeles, Andrea Rosati, Giuseppe Caruso, Khayal Gasimli, Zoia Razumova, Ilker Kahramanoglu, Nicolò Bizzarri, Aleksandra Strojna, Isabelle Ray-Coquard, Frédéric Amant, Alejandra Martinez, Viola Heinzelmann-Schwarz, Stamatios Petousis
Read the Full Article.
Title: How surgical anatomy is taught and learnt: A cross-sectional survey from the european network of young gynaecologic oncologists (ENYGO)
Authors: Andrea Rosati, Nicolò Bizzarri, Tibor Zwimpfer, Ilker Selcuk, Joanna Kacperczyk-Bartnik, Martina Angeles, Giuseppe Caruso, Esra Bilir, Khayal Gasimli, Zoia Razumova, Ilker Kahramanoglu, Houssein El Hajj, Andrej Cokan, Richard Tóth, Agnieszka Rychlik, Aleksandra Strojna, Stamatios Petousis, Frédéric Amant, Alejandra Martinez, Viola Heinzelmann-Schwarz, Denis Querleu
Read the Full Article.
Title: Understanding clinician perspectives on sexual health in gynecologic oncology: A multicountry study from the MENA region by the pan-arabian research society of gynecologic oncology (PARSGO)
Authors: Xezal Derin, Esra Bilir, Houssein El Hajj, Sara Al Rubaish, Selma Gadria, Basel Refky, Nicky Katsara-Antonakea, Sara Nasser, Jalid Sehouli
Read the Full Article.
Our abstracts are now published in International Journal of Gynecological Cancer (IJGC).”
“I’m truly honored to have participated in a amazing European Society of Gynaecological Oncology congress 2026 in Copenhagen supporting our partners at Intuitive in transforming onco-gynecologic surgery.
It was a privilege to showcase the latest capabilities of the da Vinci 5 and da Vinci Single Port robotic system-enhancing OR efficiency and improving patient outcomes, while opening new alternative approaches to surgical treatment with single incision as demonstrated during the live surgery session by Henrik Falconer.
The congress also featured numerous clinical outcome presentations where the da Vinci surgery was the method of choice, further highlighting its growing role in modern onco-gynecology.
Above all, it was a pleasure to reconnect and engage with distinguished key opinion leaders from the Czech Republic, Slovakia, and across Europe. Inspiring discussions, shared expertise, and a common vision for advancing patient care made this event truly exceptional.
A sincere thank you to Lydia Fourgeaud for the perfect organization and kind invitation-it was truly appreciated.”
“Run to believe.
A mission to improve lives.”
“ESGO2026 Wrap up!
Gynecologic oncology is becoming deeply, irreversibly personalized!
Biomarkers are THE star of the show – not just as diagnostic tools, but as the architectural blueprint for next-generation therapies.
Three pipeline mechanisms that stayed with me:
IMGN151 (AbbVie) – biparatopic FRα-targeting ADC with dual-epitope binding, 170% higher payload internalization vs. mirvetuximab, and activity retained even in low/medium FRα-expressing tumors. Phase 1 ongoing.
Relacorilant (Corcept Therapeutics) – selective GR antagonist disrupting cortisol-mediated taxane resistance, re-sensitizing tumor cells to nab-paclitaxel. Mechanistically elegant and clinically urgent. Under FDA Review, MAA submitted to EMA.
Opevesostat/MK-5684 (MSD/Orion Pharma) – first-in-class oral CYP11A1 inhibitor that blocks steroid biosynthesis at the most upstream step, eliminating a key driver of hormone-dependent tumor progression in one move. Phase 2 ongoing.
Surgical Individualization is equally moving forward. Robotics, VNOTES, tailored approaches for obese, pregnant or multimorbid patients. But with rising complexity comes a clear message: centralization is not a preference, it is a necessity. Switzerland and Germany still have meaningful ground to cover. Our Italian colleagues, shaped by people like Anna Fagotti, offer a reference point worth examining seriously.
On AI: intraoperative augmentation, preoperative decision support, nodal metastasis prediction models – the outcome data is increasingly hard to dismiss. But two questions surfaced that deserve honest answers: Who carries legal and clinical responsibility when AI de-escalates intraoperatively? And, arguably the most underappreciated challenge: if AI takes over routine surgery, how do we train the next generation of surgeons for the complex cases AI simply cannot handle?
Much to bring back to Switzerland.
And of course, the best insights come out of the conversations in between the sessions. Grateful to have made this trip with Prof. Fehr and Dr. Sell from our team in Münsterlingen/Frauenfeld.”
“We had the pleasure of presenting our multicenter retrospective study on the efficacy and safety of immunotherapy rechallenge in gynecological cancers at the ESGO 2026 Congress in Copenhagen
Our work brings together real-world data from 10 cancer care centers, offering practical insights into outcomes and tolerability of immunotherapy rechallenge in routine clinical practice. As immunotherapy continues to reshape treatment strategies, understanding its performance outside controlled trials is essential.
Meetings like ESGO remind us how powerful collaboration across institutions and countries can be.
I am especially grateful to Prof. Alexandra Leary for her mentorship and guidance throughout this project.
A heartfelt thank you to all co-investigators, research teams, and above all, to the patients who contributed to this work and agreed to participate in academic research.”
“Messages delivered:
- EMBRACE-type chemoradiation (ChRT): gold standard for locally advanced cervical cancer
- Immunotherapy with ChRT benefits selected high-risk patients
- Induction chemotherapy: not standard
- New drug trials should use EMBRACE-type ChRT as the backbone
- Brachytherapy tolerability and periprocedural care need improvement – work within the GEC ESTRO ongoing.
Thank you European Society of Gynaecological Oncology! Excellent congress!”
“Two posters from our research group Swe GCG rendered attention at European Society of Gynaecological Oncology meeting in Copenhagen. National implementation of sentinel node staging for women with endometrioid endometrial cancer and the prognostic value of radical surgery in Low-grade endometrial cancer.”
“ESGO 2026 is happening -best parts are seeing colleagues and discussing the many new treatments we are getting for patients!”
“Humbled, and grateful to the ESGO scientific and clinical community for the opportunity to present our randomized Phase II trial in platinum-resistant ovarian cancer at the ESGO 2026 Congress in Copenhagen.
Presenting data on novel therapeutic strategies in this challenging disease setting, particularly in a randomized framework, is both a privilege and a responsibility.
The level of engagement, thoughtful questions, and collegial dialogue at ESGO once again reinforced why this community is so impactful. It is inspiring to be part of a global network committed to improving outcomes for women with gynecologic cancers.
Thank you to the investigators, collaborators, patients, and study teams who made this work possible. A truly outstanding conference in Copenhagen, scientifically rigorous, forward-thinking, and deeply collaborative.”
“Looking back at the ESGO2026 Congress, for the first time the programme included a dedicated Prevention Session, organised by the European Society of Gynaecological Oncology Prevention group.
Key topics were covered during the 3-hour session:
- Primary prevention – HPV vaccination and new vaccines
- Secondary prevention – new HPV screening methods, DNA/mRNA tests, self-sampling, management of CIN / VIN / VaIN / AIN
- Tertiary prevention – prevention of surgical complications
Many thanks to the outstanding leadership of Murat Gultekin and to all speakers: Marc Arbyn, Mara Kyrgiou, Mario Preti, Vesna Kesic, Elmar Joura, Joanna Kacperczyk-Bartnik, Dimitris Haidopoulos, Mihaela Grigore. These experts not only contributed to an excellent session but are behind all the work the Prevention Committee produced during the last years.
The interest from attendees enrmous, clearly demonstrating that prevention is a priority topic for our community and should be included regularly in future ESGO congress programmes.”
Explore more oncology news and features on OncoDaily.
